Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 12/20 | 0.32 |
| ▸ | HCRTR2 | O43614 | 11/20 | 0.32 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.32 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | FABP4 | P15090 | 1/20 | 0.31 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.31 |
| ▸ | DHFR | P00374 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | CASP1 | P29466 | 1/20 | 0.30 |
| ▸ | CASP7 | P55210 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL796112 | 0.88 | KDM4E (0.33) | HCRTR1HCRTR2KMT2AL3MBTL1DHFR | |
| SCHEMBL797207 | 0.84 | KMT2A (0.34) | HCRTR1HCRTR2KMT2AL3MBTL1KDM4E | |
| SCHEMBL795997 | 0.83 | L3MBTL1 (0.32) | HCRTR1HCRTR2L3MBTL1FABP4FABP5 | |
| SCHEMBL796521 | 0.79 | KDM4E (0.33) | HCRTR1HCRTR2KMT2AL3MBTL1KDM4E | |
| SCHEMBL795936 | 0.78 | ALOX5AP (0.38) | KMT2AKDM4EALDH1A1GAAHPGD | |
| SCHEMBL796498 | 0.76 | GRM5 (0.38) | KMT2AL3MBTL1KDM4EALDH1A1GAA | |
| SCHEMBL808341 | 0.75 | PTGIR (0.34) | HCRTR1HCRTR2KMT2AKDM4EALDH1A1 | |
| SCHEMBL796525 | 0.75 | GRM5 (0.40) | KMT2AL3MBTL1DHFRKDM4EALDH1A1 | |
| SCHEMBL796111 | 0.74 | HCRTR1 (0.34) | HCRTR1HCRTR2L3MBTL1 | |
| SCHEMBL795733 | 0.74 | GRM5 (0.35) | HCRTR1HCRTR2KDM4EALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150025057-A1 | Triazine-oxadiazoles | NOVARTIS AG (CH) | 2015-01-22 | — | — | US | disclosed |
| EP-2616465-A1 | TRIAZINE-OXADIAZOLES | Novartis AG (CH) | 2013-07-24 | — | — | EP | disclosed |
| WO-2012035023-A1 | TRIAZINE-OXADIAZOLES | NOVARTIS AG (CH) | 2012-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150025057-A1 | Triazine-oxadiazoles | OPRK1, OPRD1, OPRL1 | HCRTR1 537/4885HCRTR2 204/4885CHRM2 923/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.